Drug resistance, virus fitness and HIV-1 mutagenesis

Current Pharmaceutical Design

Volumn 10, Issue 32, 2004, Pages 4065-4070

  Chen, Renxiang ^a   Quinones Mateu, Miguel E ^c   Mansky, Louis M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CEFOTAXIME; DIDANOSINE; DNA DIRECTED DNA POLYMERASE; HYDROXYUREA; LAMIVUDINE; PROTEINASE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; THYMIDINE; TIOGUANINE; VANCOMYCIN; VIF PROTEIN; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; CORRELATION FUNCTION; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS GENOME; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENESIS;

EID: 10644225293     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382404     Document Type: Review

References (71)

1. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094.
2. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001; 98: 13907-13912.
3. Pathak VK, Temin HM. 5-azacytidine and RNA secondary structure increase the retrovirus mutation rate. J Virol 1992; 66: 3093-3100.
4. Julias JG, Kim T, Arnold G, Pathak VK. The antiretrovirus drug 3′-3′-deoxythymidine increases the retrovirus mutation rate. J Virol 1997; 71: 4254-4263.
5. Julias JG, Pathak VK. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol 1998; 72: 7941-7949.
6. Mansky LM, Bernard LC. 3′-azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency type 1. J Virol 2000; 74: 9532-9539.
7. Mansky LM, Le Rouzic E, Benichou S, Gajary LC. Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol 2003; 77: 2071-2080.
8. Arion D, Sluis-Cremer N, Min K-L, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. J Biol Chem 2002; 277: 1370-1374.
9. Mansky LM. Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology 2003; 307: 116-121.
10. Mansky LM, Pearl DK, Gajary LC. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. J Virol 2002; 76: 9253-9259.
11. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999; 96: 13910-13913.
12. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Natl Med 2000; 6(12): 1375-9.
13. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77(1): 481-8.
14. Contreras AM, Hiasa Y. He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76(17): 8505-17.
15. Ruiz-Jarabo CM, Ly C, Domingo E, Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003; 308(1): 37-47.
16. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, Mullins JI. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA 1999; 96: 1492-1497.
17. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898): 646-50.
18. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002; 79(3): 285-96.
19. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002; 10(5): 1247-53.
20. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113(6): 803-9.
21. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300(5622): 1112.
22. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424(6944): 99-103.
23. Zhang H, Yang B, Pomerantz RJ, Zhang C. Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424(6944): 94-8.
24. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77(21): 11398-407.
25. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114(1): 21-31.
26. Klarmann GJ, Chen X, North TW, Preston BD. Incorporation of uracil into minus strand DNA atfects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem 2003; 278(10): 7902-9.
27. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, et al. Basic concepts in RNA virus evolution. FASEB J 1996; 10(8): 859-64.
28. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998; 279(24): 1984-91.
29. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-489.
30. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995; 345(8952): 790-1.
31. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 1999; 6(5): 298-305.
32. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000; 49: 41-66.
33. Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML, Mirza M, et al. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol 2003; 77(16): 9069-73.
34. Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996; 93(4): 1648-53.
35. Precious HM, Gunthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000; 14(1): 31-6.
36. Nijhuis M, Decks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14(1): 23-8.
37. Quinones-Mateu ME, Ball SC, Arts EJ. Role of human immunodeficiency virus type 1 group O in the AIDS pandemic. AIDS Reviews 2001; 2: 190-202.
38. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquit Immune Defic Syndr 2001; 26 Suppl 1: S10-24.
39. Goudsmit J, de Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997; 71(6): 4479-84.
40. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998; 72(5): 3773-8.
41. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-4049.
42. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699.
43. Decks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001; 26 Suppl 1: S25-33.
44. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′ -end-directed RNase H activities. J Virol 1999; 73(7): 5803-13.
45. Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, et al. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000; 74(18): 8390-401.
46. Quinones-Mateu ME, Soriano V, Domingo E, Menendez-Arias L. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology 1997; 236(2): 364-73.
47. Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 7(11): 8893-8.
48. Sniegowski PD, Gerrish PJ, Lenski RE. Evolution of high mutation rates in experimental populations of E. coli Nature 1997; 387: 703-705.
49. Bjedov I, Tenaillon O. Gerard B, Souza V, Denamur E, Radman M, et al. Stress-induced mutagenesis in bacteria, Science 2003; 300(5624): 1404-9.
50. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother 2000; 44: 1771-1777.
51. ONeill AJ, Chopra I. Use of mutator strains for characterization of novel antimicrobial agents. Antimicrob. Agents Chemother 2001; 45: 1599-1600.
52. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1254.
53. Kohler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Psudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2540-2543.
54. Mamber SW, Kolek B, Brookshire KW, Bonner DP, Fung-Tomc J. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother 1993; 37: 213-217.
55. Ren L, Rahman MS, Humayun MZ. Escherichia coli cells exposed to streptomycin display a mutator phenotype. J Bact 1999; 181: 1043-1044.
56. Negri M-F, Morosini M-I, Baquero M-R, del Campo R, Blazquez J, Baquero F. Very low cefotaxime concentrations select for hypermutable streptococcus pneumoniae populations. Antimicrob Agents Chemother 2002; 46: 528-530.
57. Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob. Agents Chemother. 2002; 46: 863-865.
58. Giraud A, Radman M, Matic I, Taddei F. The rise and fall of mutator bacteria. Curr Opin Microbiol 2001; 4: 582-585.
59. Tenaillon O, Taddei F, Radman M, Matic I. Second-order selection in bacterial evolution: selection acting on mutation and recombination rates in the course of adaptation. Res Microbiol 2001; 152: 11-16.
60. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclereq R. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003; 187(11): 1709-16.
61. Gerrish PJ, Garcia-Lerma JG. Mutation rate and the efficacy of antimicrobial drug treatment. Lancet Infect Dis 2003; 3(1): 28-32.
62. LeClerc JE, Li B, Payne WL, Cebula TA. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274: 1208-1211.
63. Radman M. Enzymes of evolutionary change. Nature 1999; 401: 866-887.
64. Denamur E, Lecointre G, Darin P, Tenaillon O, Acquaviva C, Sayada C, et al. Evolutionary implications of the frequent horizontal transfer of mismatch repair genes. Cell 2000; 103: 711-721.
65. Boshoff HI, Reed MB, Barry CE, Mizrahi V. DnaE2 Polymerase Contributes to In vivo Survival and the Emergence of Drug Resistance in Mycobacterium tuberculosis. Cell 2003; 113(2): 183-93.
66. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47(10): 3222-32.
67. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46(11): 3540-8.
68. Bjorkholm B, Sjolund M, Falk PG, Berg OG, Engstrand L, Andersson DI. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA 2001; 98(25): 14607-12.
69. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Design 2002; 8(8): 615-57.
70. el Kouni MH. Trends in the design of nucleoside analogues as anti-HIV drugs. Curr Pharm Design 2002; 8(8): 581-93.
71. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait V R, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Design 2002; 8(8): 595-614.